ArticleStem cells translational medicine2020
CD34
Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Pooled it
- Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34Experimental & molecular medicine · 2024Article
- The role of telomerase reverse transcriptase in the mitochondrial protective functions of Angiotensin-(1-7) in diabetic CD34Biochemical pharmacology · 2024Article
- CD34 positive cells as endothelial progenitor cells in biology and medicine.Frontiers in cell and developmental biology · 2023Review
- Review
- Hematopoietic Stem Cells in Wound Healing Response.Advances in wound care · 2022Article
- CD34Cellular and molecular life sciences : CMLS · 2022Article
- Transforming growth factor-β1/Thrombospondin-1/CD47 axis mediates dysfunction in CD34European journal of pharmacology · 2022Article
- Stem Cell Therapy in Limb Ischemia: State-of-Art, Perspective, and Possible Impacts of Endometrial-Derived Stem Cells.Frontiers in cell and developmental biology · 2022Review
- Coronary microvascular dysfunction: Considerations for diagnosis and treatment.Cleveland Clinic journal of medicine · 2021Review
- Transplantation of CD34+ cells for myocardial ischemia.World journal of transplantation · 2021Review
- Son of a Lesser God: The Case of Cell Therapy for Refractory Angina.Frontiers in cardiovascular medicine · 2021Review
- CD34Stem cells translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.